For Investigators

For Investigators

At Senders Research, we pride ourselves on our grounding in Good Clinical Practices. As such, we have placed GCP standards and ICH guidelines on our website for easy reference and access. We have also placed a link to Center Watch, a site that identifies new pipeline studies for which our site may be eligible. At this point, because we have developed a specialty in pediatric meningitis studies, having completed over a dozen to date, we have provided our investigators with detailed information about meningococcal and pneumococcal disease from the Centers for Disease Control and Prevention and other sources.

New data from the Centers for Disease Control and Prevention (CDC) and from Harvard University, fails to find a link between Menactra, the vaccine currently licensed to protect against meningococcal meningitis in adolescents and adults, and Guillain Barre disease, a neurologic condition. In a study of over 4.5 million 11-18 year olds, there were no cases of Guillain Barre disease in the 45 days after getting Menactra. According to Dr. Carol Baker, the chair of the Meningitis Task Force for the CDC, this study should put to rest any lingering concerns about a relationship between Menactra and Guillain Barre disease.

My irritation "button" is most easily pushed when my child:

A. ignores me when I’m telling him/her what to do.
B. whines and complains.
C. fights with a sibling.
D. talks back or acts rude.
E. some other behavior not listed.